Exposure-Response Analysis Demonstrates Predicted Exposure for Clinical Efficacy with Pridopidine 45-mg Bid Dose

被引：0
|
作者：
Geva, Michal [1 ]
McGarry, Andrew [2 ]
Gershoni-Emek, Noga [3 ]
Olanow, C. Warren [4 ]
Kieburtz, Karl [5 ]
Hayden, Michael R. [6 ]
机构：
[1] Prilenia Neurotherapeut, Herzliyya, Israel
[2] Cooper Univ Hosp, Cherry Hill, NJ USA
[3] Tel Aviv Univ, Tel Aviv, Israel
[4] Mt Sinai Sch Med, New York, NY USA
[5] Univ Rochester, Rochester, NY USA
[6] Univ British Columbia, Vancouver, BC, Canada
来源：
NEUROTHERAPEUTICS | 2020年 / 17卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
59
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [1] EXPOSURE RESPONSE ANALYSIS (PKPD) PREDICTS OPTIMAL EXPOSURE OF PRIDOPIDINE FOR CLINICAL EFFICACY OF FUNCTIONAL CAPACITY
    Geva, Michal
    McGarry, Andrew
    Emek, Noga Gershoni
    Mehra, Munish
    Olanow, C. Warren
    Kieburtz, Karl
    Hayden, Michael R.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 : A36 - A36
  • [2] ANALYSIS OF INTEGRATED SAFETY DATA FROM PRIDOPIDINE CLINICAL TRIALS DEMONSTRATES A FAVORABLE SAFETY AND TOLERABILITY PROFILE AT THE CLINICALLY RELEVANT DOSE OF 45 MG BID
    Geva, Michal
    Darpo, Borje
    Ferber, Georg
    Goldberg, Y. Paul
    Reilmann, Ralf
    Hayden, Michael R.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 : A97 - A98
  • [3] An Exposure-Response Perspective on the Clinical Dose of Pretomanid
    Nedelman, Jerry R.
    Salinger, David H.
    Subramoney, Vishak
    Woolson, Rob
    Wade, Karen
    Li, Mengchun
    Everitt, Daniel
    Mendel, Carl M.
    Spigelman, Mel
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (01)
  • [4] Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
    Jenny Zheng
    Yanke Yu
    Chandrasekar Durairaj
    Véronique Diéras
    Richard S. Finn
    Diane D. Wang
    [J]. Targeted Oncology, 2021, 16 : 69 - 76
  • [5] Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
    Zheng, Jenny
    Yu, Yanke
    Durairaj, Chandrasekar
    Dieras, Veronique
    Finn, Richard S.
    Wang, Diane D.
    [J]. TARGETED ONCOLOGY, 2021, 16 (01) : 69 - 76
  • [6] Population Pharmacokinetics, Efficacy Exposure-Response Analysis
    Chan, Phyllis
    Yu, Jiajie
    Chinn, Leslie
    Prohn, Marita
    Huisman, Jan
    Matzuka, Brett
    Hanley, William
    Tuckwell, Katie
    Quartino, Angelica
    [J]. PHARMACEUTICAL RESEARCH, 2020, 37 (02)
  • [7] DELAYED EFFECTS IN THE EXPOSURE-RESPONSE ANALYSIS OF CLINICAL QTc TRIALS
    Glomb, Patricia
    Ring, Arne
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (02) : 387 - 400
  • [8] Use of a Biomarker in Exposure-Response Analysis to Support Dose Selection for Fingolimod
    Lee, J-Y
    Wang, Y.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (08):
  • [9] POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES CONFIRM THE ALECTINIB 600 MG BID DOSE IN THE GLOBAL ALK INHIBITOR-NAIVE POPULATION.
    Hsu, J. C.
    Jaminion, F.
    Guerini, E.
    Nueesch, E.
    Balas, B.
    Zeaiter, A.
    Morcos, P. N.
    Frey, N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S69 - S69
  • [10] An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis
    Per Olsson Gisleskog
    Belén Valenzuela
    Tatiana Scherz
    Michel Burcklen
    Juan Jose Pérez-Ruixo
    Italo Poggesi
    [J]. Clinical Pharmacokinetics, 2021, 60 : 1227 - 1237
12345